New heart failure drug HJB647 enters early human testing

NCT ID NCT07465653

Recruiting now Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 13, 2026 · Updated 9 times

Summary

This early-stage study tests a new drug called HJB647 in 12 adults with chronic stable heart failure and reduced pumping ability. The main goal is to check the drug's safety and how the body processes it. Participants will receive two different doses and a placebo in a random order, with neither they nor their doctors knowing which they are getting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Jacksonville Center for Clinical
RECRUITING

Jacksonville, Florida, 32216, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nature Coast Clinical Research LLC
RECRUITING

Inverness, Florida, 34452, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Synergy Healthcare
RECRUITING

Bradenton, Florida, 34208, United States

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEART FAILURE WITH REDUCED EJECTION FRACTION